, Volume 118, Issue 3, pp 295–304 | Cite as

Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine

  • K. M. Hegadoren
  • M. T. Martin-Iverson
  • G. B. Baker
Original Investigation


Spontaneous behaviours were assessed in freely moving rats after treatment with equimolar doses of drugs that share a basic amphetamine structure. The drugs used included a psychomotor stimulant [(+)-amphetamine (AMPH)], an hallucinogen [para-methoxyamphetamine (PMA)] and the entactogens 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxy-N-ethylamphetamine (MDE). A detailed analysis of the frequency and duration of 30 different behaviours and the temporal organization of the behaviours was conducted in addition to measuring motor activity with an automated device. Levels of the biogenic amines and their acid metabolites in discrete brain regions and brain drug levels were also obtained. The automated motor activity measures discriminated among entactogens, the stimulant and the hallucinogen, but failed to distinguish between the hallucinogen and vehicle. Principal components analysis and cluster analysis of the frequencies and durations of the behaviours did not improve the classification of the drugs over the automated motor activity measures. Only the cluster analysis of the transitions between individual behaviours succeeded in differentiating the drug classes from each other and from vehicle treatment. All the behavioural measures classified one entactogen (MDE) as an hallucinogen. Cortical 5-hydroxytryptamine (5-HT) measures grouped MDE with the other entactogens but did not distinguish AMPH from vehicle. However, striatal dopamine measures differentiated AMPH from vehicle treatment. Variations in the durations of behavioural effects across drugs were associated with large differences in drug levels 3 h after injection. Although the neurochemical data provided a classification system that most closely parallels human subjective effects of these drugs, both the neurochemical and the behavioural measures supported the existence of an entactogen class distinct from a psychomotor stimulant and an hallucinogen.

Key words

Rats Entactogens Amphetamine MDMA MDA MDE PMA 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baker GB, Coutts RT, Rao TS (1987) Neuropharmacological and neurochemical properties ofN-(cyanoethyl)-β-phenylethylamine, a prodrug ofβ-phenylethylamine. Br J Pharmacol 92:243–256Google Scholar
  2. Ellison GD (1991) Animal models of hallucinations. In: Boulton AA, Baker GB, Martin-Iverson MT (eds) Neuromethods vol. 18: Animal models in psychiatry. Humana Press, Totowa, N.J., pp 151–187Google Scholar
  3. Evenden JL, Robbins TW (1983) Increased response switching, perseveration and perseverative switching followingd-amphetamine in the rat. Psychopharmacology 80:67–73Google Scholar
  4. Gibb JW, Stone D, Johnson M, Hanson GR (1990) Neurochemical effects of MDMA. In: Peroutka SJ (ed) Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Kluwer Academic Publishers, Boston, pp 133–150Google Scholar
  5. Glennon RA (1990) Serotonin receptors: clinical implications. Neurosci Biobehav Rev 14:35–47Google Scholar
  6. Glennon RA (1992) Animal models for assessing hallucinogenic agents. In: Boulton AA, Baker GB, Wu PH (eds) Neuromethods vol. 24: models of drug addiction. Humana Press, Totowa, N. J., pp 345–381Google Scholar
  7. Glennon RA, Young R (1984a) MDA: a psychoactive agent with dual stimulus effects. Life Sci 34:379–383Google Scholar
  8. Glennon RA, Young R (1984b) Further investigation of the discriminative properties of MDA. Pharmacol Biochem Behav 20:501–505Google Scholar
  9. Green AL, EI Hait MAS (1980)p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo. J Pharm Pharmacol 32:262–266Google Scholar
  10. Haberman SJ (1973) The analysis of residuals on cross-classified tables. Biometrics 29:205–220Google Scholar
  11. Hegadoren KM, Baker GB, Coutts RT (1993) The simultaneous separation and quantitation of the enantiomers of MDMA and MDA using gas chromatography with nitrogen-phosphorus detection. Res Commun Subst Abuse 14:67–80Google Scholar
  12. Hermle L, Spitzer M, Borchardt D, Kovar KA, Gouzoulis E (1993) Psychological effects of MDE in normal subjects — are entactogens a new class of psychoactive agents? Neuropsychopharmacology 8:171–176Google Scholar
  13. Hitzeman RJ, Loh HH, Domino EF (1971) Effects ofpara-methoxyamphetamine on catecholamine metabolism in the mouse brain. Life Sci 10:1087–1095Google Scholar
  14. Jacobs BL (1984) Postsynaptic serotonergic action of hallucinogens. In: Jacobs BL (ed) Hallucinogens: neurochemical, behavioral and clinical perspectives. Raven Press, New York, pp 183–202Google Scholar
  15. Jacobs BL, Trulson MC, Stern WC (1976) An animal behavior model for studying the actions of LSD and related hallucinogens. Science 194:741–743Google Scholar
  16. Johnson M, Hanson GR, Gibb JW (1987) Effects ofN-ethyl-3,4-methylenedioxyamphetamine (MDE) on central serotonergic and dopaminergic systems of the rat. Biochem Pharmacol 36:4085–4093Google Scholar
  17. Johnson M, Hanson GR, Gibb JW (1989) Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog. Eur J Pharmacol 165:315–318Google Scholar
  18. Martin WR, Vaupel DB, Nozaki M, Bright LD (1978) The identification of LSD-like hallucinogens using the chronic spinal dog. Drug Alchol Depend 3:113–123Google Scholar
  19. Martin-Iverson MT (1991) An animal model of stimulant psychoses. In: Boulton AA, Baker GB, Martin-Iverson MT (eds) Neuromethods vol. 18: Animal models in psychiatry. Humana Press, Totowa, N. J., pp 103–149Google Scholar
  20. Matthews RT, Champney TH, Frye GD (1989) Effects of (±) 3,4-methylenedioxymethamphetamine (MDMA) on brain dopaminergic activity in rats. Pharmacol Biochem Behav 33:741–747Google Scholar
  21. McKenna DJ, Guan X-M, Shulgin AT (1991) 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of3H-dopamine and3H-5-hydroxytryptamine. Pharmacol Biochem Behav 38:505–512Google Scholar
  22. Menon KM, Tseng L, Loh HH (1976) Pharmacological evidence for the central effects of monomethoxyamphetamines. J Pharmacol Exp Ther 197:272–279Google Scholar
  23. Mokler DJ, Robinson SE, Rosecrans JA (1987) (±)-3,4-Methylenedioxymethamphetamine (MDMA) produces long term reductions in brain 5-hydroxytryptamine in rats. Eur J Pharmacol 138:265–268Google Scholar
  24. Moore KE (1978) Amphetamines: biochemical and behavioral actions in animals. In: Iversen LL, Iversen SD, Synder SH (eds) Handbook of psychopharmacology vol. 11. Plenum Press, New York, pp 41–98Google Scholar
  25. Nichols DE (1986) Differences between the mechanisms of action of MDMA, MDBD and the classical hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18:305–313Google Scholar
  26. Nichols DE, Hoffman AJ, Oberlender R, Jacob P, Shulgin AT (1986) Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J Med Chem 29:2009–2015Google Scholar
  27. Nichols DE, Oberlender R (1990) Structure-activity relationships of MDMA and related compounds: a new class of psychoactive agents? In: Peroutka SJ (ed) Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Kluwer, Boston, pp 53–62Google Scholar
  28. Norton S (1968) On the discontinuous nature of behavior. J Theoret Biol 21:229–243Google Scholar
  29. Norton S (1973) Amphetamine as a model for hyperactivity in the rat. Physiol Behav 11:181–186Google Scholar
  30. Robbins TW, Mittleman G, O'Brien J, Winn P (1990) The neuropsychological significance of stereotypy induced by stimulant drugs. In: Cooper SJ (ed) Neurobiology of stereotyped behavior. Oxford University Press, London, pp 25–63Google Scholar
  31. Schmidt CJ, Taylor VL (1990) Neurochemical effects of methylenedioxymethamphetamine in the rat: acute versus long term changes. In: Peroutika SJ (ed) Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Kluwer, Boston, pp 53–62Google Scholar
  32. Segal DS, Schuckit MA (1983) Animal models of stimulant-induced psychosis. In: Creese I (ed) Stimulants: neurochemical, behavioural and clinical perspectives. Raven Press, New York, pp 131–167Google Scholar
  33. Shulgin AT (1978) Psychomimetic drugs: structure-activity relationships. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology, vol. 1. Plenum Press, New York, pp 243–333Google Scholar
  34. Shulgin AT, Nichols DE (1978) Characterization of three new psychotomimetics. In: Stillman RC, Willette RE (eds) The psychopharmacology of hallucinogens. Pergamon Press, New york, pp 74–83Google Scholar
  35. Shulgin AT, Sargent T, Naranjo C (1969) Structure-activity relationships of one-ring psychomimetics. Nature 221:537–541Google Scholar
  36. Spanos LJ, Yamamoto BK (1989) Acute and subchronic effects of methylenedioxymethamphetamine [(±) MDMA] on locomotion and the serotonin syndrome behaviour in the rat. Pharmacol Biochem Behav 32:835–840Google Scholar
  37. Thiessen PN, Cook DA (1973) The properties of 3,4-methylene-dioxyamphetamine (MDA). A review of the literature. Clin Toxicol 6:45–52Google Scholar
  38. Tseng L, Menon MK, Loh HH (1976) Comparative actions of monomethoxyamphetamines on the release and uptake of biogenic amines in brain tissue. J Pharmacol Exp Ther 197:263–271Google Scholar
  39. Winter JC (1984) The stimulus properties ofpara-methoxyamphetamine: a nonessential serotonergic component. Pharmacol Biochem Behav 20:201–203Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • K. M. Hegadoren
    • 1
  • M. T. Martin-Iverson
    • 1
  • G. B. Baker
    • 1
  1. 1.Neurochemical Research Unit, Department of PsychiatryUniversity of AlbertaEdmontonCanada

Personalised recommendations